From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Futura Medical: unlike real customers, Lucian Miers gets a stiffy on the hidden warning

By Tom Winnifrith | Wednesday 10 April 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


It was last August when Lucian Miers did some detailed on the ground research into Futura Medical (FUM) the company whose Eroxon treatment for erectile Dysfunction. No sniggering at the back about “Grandpa’s” personal needs please. The fundamental problem is that consumers seem to think that the product sucks. That is always a red flag and Lucian has been short since the low fifties. Today the shares are 36.45p following alarming annual results.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Ariana – Surprise!

Time left: 05:38:47